Key Highlights
- Nine-month Revenue rose about 26% to USD 2.6 million.
- U.S. sales grew 83% over the first nine months.
- Third-quarter EPS of negative USD 1.16 matched the estimate.
- Cash was about USD 8.2 million at September 30.
IceCure Medical (NASDAQ:ICCM) is growing fastest in the United States, where sales of its ProSense cryoablation system rose 83%. Nine-month 2026 revenue was USD 2.6 million, up about 26% from USD 2.1 million. Third-quarter revenue was USD 876.50 thousand and EPS was negative USD 1.16, both in line with estimates. Gross Profit rose about 22% to USD 762,000 from USD 626,000.
The chief executive said the period showed continued commercial momentum for ProSense, particularly in the United States. He called it the company's primary commercial market and said it is still early in realizing the opportunity.
U.S. Expansion and the ChoICE Study
The U.S. commercial footprint almost doubled, rising from 11 states in the second quarter of 2025 to 21, with dedicated sales and clinical support now in New York, Southern California, the Midwest and Florida. Management ties the commercial plan closely to the ChoICE post-marketing study, which is built to generate clinical evidence while giving physicians experience with the system.
Centers in Tennessee, California and Oregon are among its three clinical sites, and enrollment and treatment have started. Management later put the current count at four sites, with more being finalized. Early participants include physicians already familiar with ProSense and a first-time user in Oregon, who described it as a simple, minimally invasive option.
Abroad, it cited regulatory approval in China, an exclusive distribution agreement in the Netherlands and two further peer-reviewed publications on cryoablation in breast cancer. Talks with potential Chinese partners are under way, chiefly over distribution.
Spending, Losses and Cash
Research and development expenses were about USD 6.5 million versus USD 5.1 million, a rise the company tied to the ChoICE study and other clinical work. Sales and Marketing expenses grew about 20% to USD 3.6 million, and general and administrative expenses were about USD 3.5 million versus USD 3.3 million. Operating loss and net loss each came to about USD 12.9 million, up from USD 10.8 million a year earlier.
Cash and cash equivalents were about USD 8.2 million at September 30, against about USD 8.9 million at year-end 2025. The company says it is keeping a tight rein on financial resources while investing in commercial, clinical and organizational capabilities it expects to support long-term growth, among them the U.S. commercial team and the ChoICE study.
Seasonality and the Outlook
According to the CFO, the first and third quarters tend to be softer and the fourth is typically the best. A U.S. executive said sales revenue has risen quarter over quarter as traction builds. Internal projections for next year, the CFO said, point to healthy double-digit revenue growth, but no formal guidance is given.
Whether the 400-patient enrollment goal can be met within three years is too early to call, the chief executive said, and talks with the FDA continue. A month earlier the U.S. commercial team numbered seven, and nine is being considered by year-end.
More ChoICE sites, further U.S. state expansion, international distribution and the cash position while research spending carries on are the points to follow.




_11_19_2026_19_57_40_035532.jpg)

Please wait processing your request...